Long-term Survival Benefit Demonstrated in Phase 2 ReACT Study of RINTEGA(R) in Recurrent Bevacizumab-naive Glioblastoma
November 20, 2015 at 14:32 PM EST
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today presented mature survival data from the Company's randomized, double-blind Phase 2 study ...